ArticleBlood cancer journal2018

Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea.

Rossella Renso et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.